NCT01647555

Radiotherapy in Association With Cetuximab in Patients Treated for an Epidermoid Cancer

Prospective Study About the Association of Radiotherapy and Cetuximab in the Treatment of Epidermoid Cancers, Locally Advanced, of the Head and Neck.

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 57 (actual)
• Sponsor: Centre Oscar Lambret · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study evaluates the skin toxicities in patients with epidermoid cancer, treated by Radiotherapy in association with Cetuximab.

Detailed description

This prospective and multicentric study evaluates the skin toxicities in patients with locally Advanced head and neck epidermoid cancer, treated by Radiotherapy in association with Cetuximab.

Conditions

• Epidermoid Head and Neck Cancer

Interventions

Type	Name	Description
DRUG	Cetuximab	First cycle: 400 mg/m2 Next cycles: 250 mg/m2
RADIATION	Radiotherapy	Curative dose: 66 to 70 Gy

Timeline

• Start date: 2006-10-06
• Primary completion: 2012-10-01
• Completion: 2014-10-01
• First posted: 2012-07-23
• Last updated: 2026-03-18

Locations

7 sites across 1 country: France